1. MAPK/ERK Pathway Immunology/Inflammation
  2. MNK PD-1/PD-L1
  3. Tomivosertib

Tomivosertib (eFT508) est un inhibiteur puissant, hautement sélectif de MNK1 et de MNK2 et oralement actif, avec IC50s de 1-2 nM contre les deux isoformes. Le traitement au tomivosertib (eFT508) entraîne une réduction dose-dépendante de la phosphorylation de eIF4E à la sérine 209 (IC50=2-16 nM) dans les lignées cellulaires tumorales. Tomivosertib (eFT508) régule également considérablement l'abondance des protéines PD-L1.

Tomivosertib (eFT508) ist ein potenter, hochselektiver und oral aktiver MNK1 und MNK2-Inhibitor mit IC50s von 1-2 nM gegen beide Isoformen. Die Behandlung mit Tomivosertib führt zu einer dosisabhängigen Reduktion der eIF4E-Phosphorylierung bei Serin 209 (IC50=2-16 nM) in Tumorzelllinien. Tomivosertib reguliert auch die PD-L1-Proteinhäufigkeit dramatisch herunter.

Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 1849590-01-7

사이즈 가격 재고 수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
해외재고보유
Solution
10 mM * 1 mL in DMSO 해외재고보유
Solid
1 mg 해외재고보유
5 mg 해외재고보유
10 mg 해외재고보유
25 mg 해외재고보유
50 mg 해외재고보유
100 mg 해외재고보유
200 mg   견적 받기  
500 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 13 publication(s) in Google Scholar

Other Forms of Tomivosertib:

Top Publications Citing Use of Products

    Tomivosertib purchased from MedChemExpress. Usage Cited in: Brain. 2024 Jul 24:awae178.  [Abstract]

    MNK inhibition with eFT508 (Tomivosertib: 25 nM) rapidly decreases phosphorylated eIF4E in human dorsal root ganglion neurons. Representative enlarged images of p-eIF4E immunostaining (red) and neuronal marker, peripherin (blue).

    Tomivosertib purchased from MedChemExpress. Usage Cited in: Brain. 2024 Jul 24:awae178.  [Abstract]

    Treatment with eFT508 (Tomivosertib: 25 nM) reverses spontaneous activity in human dorsal root ganglion neurons associated with painful dermatomes.

    Tomivosertib purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2022 Sep;18(9):942-953.  [Abstract]

    Immunoblot analysis was performed on PANC-1 cell lysates to detect the expression of phosphorylated eIF4E (Ser 209; p-eIF4E), total eIF4E, and actin. These cells were treated with DMSO, CID661578, cercariaein, CGP57380, or eFT508 (Tomivosertib: 40 μM) for 6 hours.

    Tomivosertib purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2022 Sep;18(9):942-953.  [Abstract]

    Six-day-old zebrafish larvae underwent β-cell ablation and were treated with DMSO, CID661578, eFT508, or a combination of CID661578 and eFT508 (Tomivosertib: 10 μM) for 48 hours. The number of β-cells was then quantitatively analyzed.

    Tomivosertib purchased from MedChemExpress. Usage Cited in: Oncogene. 2021 Mar;40(10):1851-1867.  [Abstract]

    Protein levels of eIF4E and MCL1 in LPS141 and MESSA cells upon treatment with eFT508 (30 μM, 24 h). The result indicates a inhibition of p-4E at 30 μM.

    View All MNK Isoform Specific Products:

    • Biological Activity

    • 순도&문서

    • References

    • 고객리뷰

    제품 설명

    Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines[1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance[2].

    IC50 & Target[1]

    MNK1

    1-2 nM (IC50)

    MNK2

    1-2 nM (IC50)

    PD-L1

     

    Cellular Effect
    Cell Line Type Value Description References
    A2780 GI50
    > 50 μM
    Compound: eFT508
    Antiproliferative activity against human A2780 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    [PMID: 31362920]
    A549 IC50
    > 50 μM
    Compound: eFT508; 1
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    [PMID: 38564512]
    DOHH-2 IC50
    6.3 μM
    Compound: eFT508; 1
    Antiproliferative activity against human DOHH-2 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    Antiproliferative activity against human DOHH-2 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    [PMID: 38564512]
    HCT-116 GI50
    27.93 μM
    Compound: eFT508
    Antiproliferative activity against human HCT116 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    [PMID: 31362920]
    HL-60 GI50
    > 50 μM
    Compound: eFT508
    Antiproliferative activity against human HL60 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    [PMID: 31362920]
    HT-29 IC50
    > 50 μM
    Compound: eFT508; 1
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    [PMID: 38564512]
    K562 IC50
    13.54 μM
    Compound: eFT508
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 30824167]
    LN-18 IC50
    6.27 μM
    Compound: eFT508; 1
    Antiproliferative activity against human LN-18 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    Antiproliferative activity against human LN-18 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    [PMID: 38564512]
    MDA-MB-231 IC50
    45 μM
    Compound: eFT508; 1
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    [PMID: 38564512]
    MOLM-13 GI50
    33.04 μM
    Compound: eFT508
    Antiproliferative activity against human MOLM13 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MOLM13 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    [PMID: 31362920]
    MV4-11 GI50
    9.26 μM
    Compound: eFT508
    Antiproliferative activity against human MV4-11 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    [PMID: 31362920]
    MV4-11 IC50
    14.49 μM
    Compound: eFT508
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 30824167]
    PANC-1 IC50
    > 50 μM
    Compound: eFT508; 1
    Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    [PMID: 38564512]
    PC-3 GI50
    > 50 μM
    Compound: eFT508
    Antiproliferative activity against human PC3 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    [PMID: 31362920]
    PC-3 IC50
    29.4 μM
    Compound: eFT508; 1
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    [PMID: 38564512]
    SK-OV-3 GI50
    > 50 μM
    Compound: eFT508
    Antiproliferative activity against human SKOV3 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    [PMID: 31362920]
    TMD8 IC50
    2.53 μM
    Compound: eFT508
    Antiproliferative activity against human TMD8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human TMD8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 30824167]
    TMD8 IC50
    > 50 μM
    Compound: eFT508; 1
    Antiproliferative activity against human TMD8 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    Antiproliferative activity against human TMD8 cells assessed as inhibition of cell growth incubated for 72 hrs MTS assay
    [PMID: 38564512]
    In Vitro

    Tomivosertib (eFT508) reduces eIF4E phosphorylation dose-dependently at serine 209 (IC50=2-16 nM) in tumor cell lines. In a panel of appr 50 hematological cancers, Tomivosertib shows anti-proliferative activity against multiple DLBCL cell lines. Sensitivity to Tomivosertib in TMD8, OCI-Ly3 and HBL1 DLBCL cell lines is associated with dose-dependent decreases in production of pro-inflammatory cytokines including TNFα, IL-6, IL-10 and CXCL10. Further evaluation Tomivosertib mechanism of action demonstrates that decreased TNFα production correlates with a 2-fold decrease in TNFα mRNA half-life[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Tomivosertib (eFT508) shows significant anti-tumor activity in the TMD8 and HBL-1 ABC-DLBCL models, both of which harbor activating MyD88 mutations. Besides, Tomivosertib combines effectively with components of R-CHOP and with novel targeted agents, including PCI-32765 and Venetoclax, in human lymphoma models[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    분자량

    340.38

    화학식

    C17H20N6O2

    CAS No.
    Appearance

    Solid

    Color

    Off-white to yellow

    SMILES

    O=C(C1=C(C)C=C(NC2=NC=NC(N)=C2)C(N13)=O)NC43CCCCC4

    선적

    Room temperature in continental US; may vary elsewhere.

    보관
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    용액&용해도
    In Vitro: 

    DMSO : 8 mg/mL (23.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.9379 mL 14.6895 mL 29.3789 mL
    5 mM 0.5876 mL 2.9379 mL 5.8758 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • 몰농도 계산기

    • 농도 희석 계산기

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    순도&문서

    Purity: 99.75%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.9379 mL 14.6895 mL 29.3789 mL 73.4473 mL
    5 mM 0.5876 mL 2.9379 mL 5.8758 mL 14.6895 mL
    10 mM 0.2938 mL 1.4689 mL 2.9379 mL 7.3447 mL
    15 mM 0.1959 mL 0.9793 mL 1.9586 mL 4.8965 mL
    20 mM 0.1469 mL 0.7345 mL 1.4689 mL 3.6724 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    최근 본 상품:

    온라인 문의

    Your information is safe with us. * Required Fields.

    상품명

     

    Requested Quantity *

    고객명 *

     

    호칭

    메일주소 *

     

    전화번호 *

    Department

     

    회사명 *

    City

    Country or Region *

         

    비고

    대량구매 문의

    Inquiry Information

    상품명:
    Tomivosertib
    Cat. No.:
    HY-100022
    수량:
    MCE Japan Authorized Agent: